Armodafinil Complete Pharmacology
Chemical Structure and Formulation
Armodafinil is the R-enantiomer of racemic modafinil, a wakefulness-promoting agent with distinct pharmacokinetic advantages over its racemic parent compound. 1
- Molecular formula: C15H15NO2S with molecular weight of 273.35 1
- Chemical name: 2-[(R)-(diphenylmethyl)sulfinyl]acetamide 1
- Physical properties: White to off-white crystalline powder, slightly soluble in water, sparingly soluble in acetone, soluble in methanol 1
- Available formulations: Oral tablets in 50,150,200, or 250 mg strengths 1
- Inactive ingredients: Croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch 1
Pharmacokinetics
Absorption
Armodafinil is readily absorbed with peak plasma concentrations reached approximately 2 hours after administration in the fasted state. 2
- Bioavailability: Food delays peak concentration by 2-4 hours but does not affect overall bioavailability 2
- Dose proportionality: Linear pharmacokinetics demonstrated over the 50-400 mg dose range 2
- Time to peak (Tmax): Median of approximately 2 hours when fasted 2, 3
Distribution
- Plasma concentration profile: After reaching Cmax, plasma concentrations decline in a monophasic manner 2, 3
- Comparative profile: Armodafinil maintains higher plasma concentrations later in the day compared to racemic modafinil on a milligram-to-milligram basis 3
- AUC comparison: Mean AUC values are 33-40% higher with armodafinil compared to equivalent doses of modafinil 3
Metabolism
Armodafinil is metabolized primarily in the liver into inactive acid and sulfone metabolites. 4
- Primary metabolic pathway: Hepatic metabolism to inactive metabolites 4
- CYP enzyme interactions:
Elimination
The mean elimination half-life of armodafinil is approximately 15 hours, with primarily renal excretion of inactive metabolites. 2
- Half-life: Approximately 13-15 hours 2, 3
- Elimination route: Primarily renal excretion of metabolites 4
- Steady state: Reached within 7 days of once-daily dosing 2
- Accumulation: At steady state, systemic exposure is 1.8 times that of single-dose administration 2
- Elimination pattern: Monophasic decline versus biphasic decline seen with racemic modafinil (due to rapid elimination of S-isomer) 3
Pharmacodynamics
Mechanism of Action
Although not fully clarified, major effects appear to be associated with inhibition of dopamine reuptake and modulation of multiple neurochemical pathways. 4
- Primary mechanism: Dopamine reuptake inhibition 4
- Secondary pathways modulated:
Clinical Effects on Alertness
Armodafinil improves wakefulness in a dose-dependent manner, with effects lasting longer than equivalent doses of modafinil. 6
- Wakefulness improvement: All doses (100-300 mg) significantly increased Maintenance of Wakefulness Test latencies compared to placebo (p < 0.0001) 6
- Sustained attention: Reduced Psychomotor Vigilance Task lapses across all doses (p < 0.0001) 6
- Duration of effect: Armodafinil 200 mg showed longer MWT latencies and fewer PVT lapses 6-14 hours post-dose compared to modafinil 200 mg 6
- Dose-response relationship: Magnitude and duration of effects at later time points are dose and concentration dependent 6
FDA-Approved Indications
Armodafinil is FDA-approved for improving wakefulness in adults with excessive sleepiness due to narcolepsy, obstructive sleep apnea, or shift work disorder. 1
Narcolepsy
- Recommendation strength: Conditional recommendation from American Academy of Sleep Medicine (2021) 7
- Evidence quality: Moderate quality evidence 7
- Clinical efficacy: Demonstrated clinically significant improvements in excessive daytime sleepiness and disease severity 7
- Dosing timing: Typically administered once daily in the morning 1
Obstructive Sleep Apnea (OSA)
- Adjunctive therapy: Used with other medical treatments; does not replace CPAP or other prescribed treatments 1
- Suboptimal CPAP adherence: In patients with 2-4 hours/night CPAP usage, 150 mg daily armodafinil significantly decreased ESS by 5.03 ± 4.22 (p < 0.001) over 12 weeks 8
- Sleep quality improvement: PSQI significantly decreased by 5.27 ± 2.93 (p < 0.001) 8
- CPAP adherence: Trend toward improvement from 2.99 ± 0.63 h/night to 3.47 ± 1.38 h/night (p = 0.09) 8
Shift Work Disorder (SWD)
- Dosing timing: Administered approximately 1 hour before work shift 1
- Important caveat: Taking armodafinil too close to bedtime may impair ability to fall asleep 1
Posttraumatic Hypersomnia
- Recommendation strength: Conditional recommendation from American Academy of Sleep Medicine (2021) for hypersomnia secondary to traumatic brain injury 7
- Evidence quality: Moderate quality evidence 7
- Clinical efficacy: One RCT demonstrated clinically significant improvement in excessive daytime sleepiness in TBI patients 7
Dosing and Administration
Armodafinil should be taken exactly as prescribed, with timing adjusted based on the specific sleep disorder being treated. 1
- Standard dosing: Prescribed dose should not be changed without consulting physician 1
- Administration: Can be taken with or without food 1
- Narcolepsy/OSA: Once daily in the morning 1
- Shift work disorder: Approximately 1 hour before work shift 1
- Timing considerations: Do not change time of day without consulting physician 1
Adverse Effects
Common Adverse Events
The most frequently reported adverse events include headache, upper respiratory tract infections, dizziness, nausea, sinusitis, and somnolence. 7
- Headache: Most common across all studies 7, 2, 6
- Gastrointestinal: Nausea, diarrhea, abdominal pain 2, 6
- Neurological: Dizziness 2, 6
- Respiratory: Upper respiratory tract infections, sinusitis 7
- Sleep-related: Insomnia (paradoxical) 4
- Cardiovascular: Tachycardia/palpitations, increased blood pressure and heart rate 4, 6
- Other: Dry mouth, decreased appetite 4
- Severity: Most adverse events are mild to moderate 7
- Tolerability: Generally well tolerated in clinical studies 2, 5, 8
Serious Adverse Effects
Serious rash or allergic reactions affecting liver or blood cells may occur and can be life-threatening, requiring immediate discontinuation and emergency medical attention. 1
Dermatologic emergencies:
Systemic allergic reactions:
Drug Interactions
Hormonal Contraceptives
Armodafinil reduces the effectiveness of hormonal birth control methods, requiring alternative or additional contraception during treatment and for one month after discontinuation. 7, 1
- Affected methods: Birth control pills, shots, implants, patches, vaginal rings, and intrauterine devices 1
- Increased pregnancy risk: Women using hormonal contraception have higher chance of pregnancy while taking armodafinil 1
- Duration of risk: Continues for one month after final dose 1
- Management: Use effective non-hormonal birth control during treatment and for one month after stopping 1
CYP3A4 Substrates
As a moderate CYP3A4 inducer, armodafinil may require dosage adjustments for drugs metabolized by this enzyme. 5
- Affected medications: Ciclosporin, triazolam, and other CYP3A4 substrates 5
- Effect magnitude: Reduces oral midazolam AUC by 32% and Cmax by 19% 5
- Clinical implication: Dosage adjustments may be required 5
CYP2C19 Substrates
As a moderate CYP2C19 inhibitor, armodafinil increases exposure to drugs metabolized by this enzyme. 5
- Affected medications: Diazepam, phenytoin, omeprazole, and other CYP2C19 substrates 5
- Effect magnitude: Increases omeprazole AUC by 38% 5
- Clinical implication: Dosage adjustments may be required 5
Other Interactions
- CYP1A2: No induction observed with caffeine as probe substrate 5
- CNS depressants: Caution advised when combining with alcohol and sedating medications 7
Special Populations
Pregnancy
Based on animal data and registry findings, armodafinil may cause fetal harm, with a 2018 registry report showing higher rates of major congenital anomalies in exposed pregnancies. 7
- Animal data: May cause fetal harm 7
- Human data: Insufficient to determine risk 7
- Registry findings (2018): Higher rate of major congenital anomalies and other adverse reactions in children exposed in utero 7
- 14-year registry update (2024): Prevalence of major congenital malformations was 13.1% (95% CI, 8.0-20.0) among prospective live births, compared to 3% MACDP population-based rate 9
- First trimester exposure: MCM prevalence of 13.7% after first trimester exposure 9
- Other outcomes: Preterm births (10.2%), IUGR (2.2%), and LBW/VLBW (8.0%) were within expected background rates 9
- Pregnancy registry: Available at 1-866-404-4106 for enrollment and information 1
- Risk-benefit consideration: Balance of risks and harms is likely different for pregnant women 7
Breastfeeding
Limited data suggest relatively small amounts of armodafinil pass into human milk, with consequent limited infant exposure, though monitoring is required. 1, 10
- Milk transfer: Unknown if armodafinil passes into milk per FDA label 1
- Case study findings: Average concentration in human milk was 1.96 mg/L 10
- Relative infant dose: 4.85% 10
- Theoretical infant dose: 0.294 mg/kg/day 10
- Infant plasma concentration: 0.19 mg/L (maternal: 12.02 mg/L) 10
- Clinical outcome: Infant had normal growth and development with exclusive breastfeeding 10
- Recommendation: Consideration can be given to use during breastfeeding provided infant is monitored 10
- Risk-benefit consideration: Balance of risks and harms is likely different for breastfeeding women 7
Pediatric Population
Armodafinil is not approved for use in children for any medical condition, and safety and effectiveness in children under 18 years have not been established. 1
- FDA approval status: Not approved for pediatric use 1
- Safety data: Unknown if safe and effective in children under 18 years 1
- Dermatologic concerns: Severe dermatologic effects including Stevens-Johnson Syndrome reported in children with modafinil 4
Hepatic and Renal Impairment
- Hepatic metabolism: Primarily metabolized in liver 4
- Renal excretion: Metabolites undergo primarily renal excretion 4
- Monitoring: Patients with liver or kidney problems should inform their physician 1
Contraindications
Armodafinil is contraindicated in patients with known hypersensitivity to armodafinil, modafinil, or any tablet ingredients. 1
- Allergy to ingredients: Any component of armodafinil tablets 1
- Previous reactions: History of rash or allergic reaction to armodafinil (NUVIGIL®) or modafinil (PROVIGIL®) 1
- Cross-reactivity: These medicines are very similar 1
Precautions and Warnings
Controlled Substance Status
Armodafinil is a Schedule IV federally controlled substance with potential for abuse or dependency. 7, 1
- DEA classification: Schedule IV 7, 1
- Abuse potential: Can be abused or lead to dependence 1
- Storage: Keep in safe place to prevent misuse and abuse 1
- Distribution: Selling or giving away is against the law and may harm others 1
- History screening: Inform physician of any history of alcohol, prescription medicine, or street drug abuse/dependence 1
- Clinical note: Intoxication and dependence associated with modafinil are uncommon 4
Cardiovascular Monitoring
Blood pressure monitoring is recommended during armodafinil treatment due to potential increases in blood pressure and heart rate. 1, 6
- Hypertension: Blood pressure may need more frequent monitoring 1
- Cardiovascular history: Inform physician of heart problems or previous heart attack 1
- Observed effects: Increased mean blood pressure and reports of tachycardia/palpitations in clinical studies 6
Psychiatric Considerations
Patients with history of mental health problems including psychosis should be monitored carefully during armodafinil treatment. 1
- Mental health history: Inform physician of any history of mental health problems 1
- Psychosis risk: Specific concern for patients with history of psychosis 1
Sleep Hygiene
Armodafinil does not cure sleep disorders or replace the need for adequate sleep; patients must continue good sleep habits and other prescribed treatments. 1
- Not a cure: Will not cure narcolepsy, OSA, or shift work disorder 1
- Residual sleepiness: May help sleepiness but may not stop all sleepiness 1
- Sleep replacement: Does not replace getting enough sleep 1
- Comprehensive management: Follow physician's advice about good sleep habits and other treatments 1
- CPAP continuation: For OSA patients, continue using CPAP machine and other prescribed treatments 1
Clinical Efficacy Evidence
Quality of Evidence
The American Academy of Sleep Medicine rates the overall quality of evidence for armodafinil as moderate across approved indications. 7
- Evidence grading: Moderate quality 7
- Downgrading reason: Imprecision in available studies 7
- Recommendation strength: Conditional recommendations for all indications 7
Comparative Effectiveness
Despite having the same terminal half-life as modafinil, armodafinil maintains substantially different pharmacokinetic profiles with higher late-day plasma concentrations. 3
- Half-life similarity: Both approximately 13 hours 3
- Cmax comparison: Similar mean maximum plasma concentrations 3
- Tmax comparison: Similar median time to Cmax 3
- Elimination pattern difference: Monophasic (armodafinil) versus biphasic (modafinil) 3
- AUC advantage: 33% higher AUClast and 40% higher AUCinfinity with armodafinil 3
- Clinical implication: Higher plasma concentrations late in day may result in improved wakefulness throughout the day 3
Overdose Management
In case of overdose, contact physician or poison control center immediately. 1